The company will hold a conference call and an online presentation on the same day at
Contact:
Tel: +46 18-50 54 40
Email: IR@oasmia.com
About
Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on the Company's proprietary drug delivery technology platform XR-17 which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea (paclitaxel micellar). Apealea has received market authorization in the
(C) 2021 Electronic News Publishing, source